X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.
Lead Product(s): Merigolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TU2670
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SK Chemicals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
